Anaplastic lymphoma kinase (ALK) rearrangement, is a kind of driver mutation, accounts for 3%-5% of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion genes have distinct clinical features and good response to ALK inhibitors. Metastasis from lung cancer to the ovary has rarely been known. We report a case of a 54-year-old woman with bilateral ovarian metastases from ALK rearranged NSCLC. She underwent bilateral salpingo-oophorectomy for ovary masses, which were progressed after cytotoxic chemotherapy although primary lung mass was decreased. Histopathological examination of the ovary tumor showed characteristic adenocarcinoma patterns of the lung and ALK rearrangement.
ObjectiveTo evaluate the inter-vendor and inter-session reliability of diffusion tensor imaging (DTI) and relevant parameters.Materials and MethodsThis prospective study included 10 healthy subjects (5 women and 5 men; age range, 25–33 years). Each subject was scanned twice using 3T magnetic resonance scanners from three different vendors at two different sites. A voxel-wise statistical analysis of diffusion data was performed using Tract-Based Spatial Statistics. Fractional anisotropy (FA), mean diffusivity (MD), and radial diffusivity (RD) values were calculated for each brain voxel using FMRIB's Diffusion Toolbox.ResultsA repeated measures analysis of variance revealed that there were no significant differences in FA values across the vendors or between sessions; however, there were significant differences in MD values between the vendors (p = 0.020). Although there were no significant differences in inter-session MD and inter-session/inter-vendor RD values, a significant group × factor interaction revealed differences in MD and RD values between the 1st and 2nd sessions conducted by the vendors (p = 0.004 and 0.006, respectively).ConclusionAlthough FA values exhibited good inter-vendor and inter-session reliability, MD and RD values did not show consistent results. Researchers using DTI should be aware of these limitations, especially when implementing DTI in multicenter studies.
Background/Aims:This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naïve CHB patients.Patients and Methods:We performed a retrospective cohort study of treatment-naive CHB patients who were treated with TDF or ETV. We analyzed virologic, biochemical, and serologic responses at 3, 6, and 12 months.Results:A total of 107 patients (TDF group = 49, ETV group = 58) were included. Baseline characteristics were similar between the two groups. The estimated proportion of complete virologic response (CVR) in the TDF or ETV group was 44.9% versus 39.7% at 6 months and 89.6% versus 83.2% at 12 months, respectively (P = 0.991). Viral breakthrough was not observed in both groups. One patient in the TDF group and two patients in the ETV group experienced HBeAg loss, respectively (P = 0.657). High HBV DNA level at baseline was a significant negative predictor of virologic response by Cox regression analysis (P = 0.007). The safety profile was similar between the two groups. There was no case with serious adverse event.Conclusions:Both TDF and ETV were effective in achieving CVR and had a favorable safety profile in treatment-naïve CHB patients. High viral load at baseline was a negative predictive factor of CVR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.